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substantial metabolic requirements on the supply of glucose and energy. Given the high frequency of genetic lesions present on B-lymphoid transcription factors in pre-B ALL, we investigated whether these transcription factors restrict the supply of glucose and energy, and thus represent a metabolic barrier against malignant transformation.
Studying inactivating lesions in PAX5, IKZF1, EBF1 and TCF3 in 279 patient samples from clinical trials for children and adults (see Methods), we found mutations or deletions in 209 cases. The patient-derived pre-B ALL xenografts that we studied here exhibited abnormal expression of PAX5 and IKZF1 proteins (Extended Data Fig. 1b, c) . Analysis of chromatin immunoprecipitation with sequencing (ChIP-seq) data of human B-cells revealed that PAX5, IKZF1, EBF1 and TCF3 bind to promoter regions of INSR, GLUT1, GLUT6, G6PD and HK2, genes encoding proteins that enable glucose uptake and utilization. We also observed binding peaks at promoter regions of genes that encode negative regulators of glucose uptake, including NR3C1, TXNIP and CNR2. Recruitment of PAX5 to these promoters was confirmed by single-locus quantitative ChIP (Extended Data Fig. 1d, e ). Inducible reconstitution of mouse Pax5 (Gene Expression Omnibus (GEO) accession number: GSE52870) in Pax5-deficient pre-B leukaemia cells downregulated multiple mediators of glucose uptake, whereas the mRNA levels of glucose-transport inhibitors increased (Mlxip, Txnip, Cnr2; Extended Data Fig. 1a ).
We verified these results in four patient-derived pre-B ALL samples. Inducible reconstitution of wild-type transcription factors in patient-derived pre-B ALL cells lacking functional PAX5 or IKZF1 ( Fig. 1a ) induced activation of the LKB1-AMPK energy-stress-sensor pathway 15 . As would be consistent with the depletion of glucose and energy, reconstitution of IKZF1 and PAX5 diminished AKT activation. Similarly, reconstitution of both IKZF1 and PAX5 decreased protein levels of the insulin receptor, the glucose transporters GLUT1, GLUT3 and GLUT6, and the effectors of glucose metabolism HK2, HK3, PFKL, PGAM, PYGL and G6PD. By contrast, PAX5 and IKZF1 induced strong expression of the glucose-transport inhibitors NR3C1, TXNIP and CNR2 [8] [9] [10] . For loss-of-function studies, dominant-negative variants of IKZF1 (DN-IKZF1, lacking zinc fingers 1-4) and PAX5 (DN-PAX5; a PAX5-ETV6 fusion gene) were cloned from patient samples and expression was induced in two pre-B ALL xenografts carrying wildtype IKZF1 and PAX5 alleles (Extended Data Fig. 2a ). As expected, most PAX5-and IKZF1-induced changes in protein expression were reversed by DN-IKZF1 and DN-PAX5 ( Fig. 1a ).
Inducible reconstitution of PAX5 or IKZF1 in human pre-B ALL cells resulted in the depletion of cells in competitive-growth assays, in parallel with reduced glucose uptake and ATP depletion. Conversely, DN-PAX5 and DN-IKZF1 conferred a net survival advantage, as measured in competitive-growth assays, and increased glucose uptake and cellular ATP levels (Fig. 1b, c) . Since oncogenic kinases such as BCR-ABL1 require large amounts of ATP, B-lymphoid transcription factors may function as metabolic gatekeepers, limiting ATP supply to levels that are insufficient for malignant transformation. To test this theory, we studied glucose uptake, glycolysis and ATP levels in pre-B cells from Pax5 wild-type and Pax5 haploinsufficient mice 16 in the presence and absence of a BCR-ABL1 transgene. In the presence of wild-type Pax5, the BCR-ABL1 transgene failed to increase glucose uptake and ATP levels, and glycolytic activity increased only modestly. However, in Pax5-haploinsufficient pre-B cells, BCR-ABL1 markedly increased glucose uptake (> 50-fold), glycolytic capacity (> 10-fold) and cellular ATP levels (> 25-fold). These findings provide genetic evidence for the PAX5-mediated restraint of glucose uptake and energy supply in pre-B cells (Extended Data Fig. 2 ).
Both B-lymphoid and myeloid leukaemia typically arise from a multipotent progenitor cell and often carry the same oncogenes. Despite this common origin, B-lymphoid and myeloid leukaemia differ fundamentally in their biological and clinical characteristics. Given that myeloid or B-lymphoid fates are instructed by transcription factors (myeloid by CEBPA, lymphoid by IKZF1 and PAX5) that regulate glucose and energy metabolism 14, 15 , we investigated whether myeloid and B-cell identities are linked to distinct metabolic states. Metabolic comparisons of B-lineage Philadelphia-chromosome-positive (Ph + ) ALL and myeloid chronic myeloid leukaemia (CML) cells revealed marked differences. Intracellular glucose and pyruvate were present at notably higher levels (approximately 10-13-fold and 6-11-fold, respectively) in patient-derived myeloid cells compared to B-lymphoid leukaemia cells. Myeloid leukaemia cells had abundant ATP reserves, whereas ATP levels in B-lineage leukaemia cells were low, indicating a state of chronic energy stress ( Fig. 2a ). Bioenergetic analyses revealed lower glycolytic reserves (approximately 5-14-fold) in B-lymphoid than in myeloid leukaemia cells. Basal and maximum respiration and mitochondrial ATP levels were substantially lower in B-lineage leukaemia cells (Extended Data Fig. 3a ), resulting in the constitutive activation of the LKB1-AMPK energy-stress-sensor pathway. Ph + ALL cells expressed effectors of glucose utilization (GLUT1, HK2, HK3, G6PD) at more than 10-fold lower levels than myeloid leukaemia cells, whereas the expression of glucose transport inhibitors (NR3C1, TXNIP, CNR2; Fig. 2b ) was substantially higher in B-lymphoid cells than in CML cells.
To examine the effects of B-cell-and myeloid-lineage identity in genetically identical mouse leukaemia cells, we studied the reprogramming of B-cells through the inducible overexpression of the myeloid transcription factor CEBPα . Studying changes in gene expression during B-to-myeloid cell reprogramming 12 , we observed the upregulation of Insr, Glut1, Glut6, Hk2, Hk3, G6PD and Pygl, effector molecules of glucose transport and utilization. B-to-myeloid cell reprogramming markedly increased glucose uptake and cellular ATP levels ( Fig. 2c ), resulting in decreased Lkb1-Ampk pathway activity (Extended Data Fig. 3 ). Mirroring these differences, the Cre-mediated deletion of Stk11 (also known as Lkb1) induced cell death in B-lineage ALL cells, but accelerated proliferation in B-to-myeloid reprogrammed cells ( Fig. 2d ).
For this reason, we studied the consequences of inducible ablation of Lkb1 and Prkaa2 (also known as Ampka2), expression levels of which were upregulated at the pre-B-cell stage compared to later stages of B-cell development (GEO accession number: GSE38463). The Cremediated 4-hydroxytamoxifen (4-OHT)-induced deletion of Lkb1 or Ampka2 led to rapid leukaemia cell death, prevented malignant transformation of pre-B cells and affected the development of leukaemia in vivo. Deletion of Lkb1 or Ampka2 significantly prolonged the overall survival of mouse recipients ( Fig. 2e , f and Extended Data Fig. 4 ).
The genotyping of leukaemias revealed that floxed alleles of Lkb1 and Ampka2 were retained in all cases (Extended Data Fig. 4i ), indicating strong positive selection for the few clones that escaped Cre-mediated deletion.
A recent study showed that deletion of Prkaa1 (also known as Ampka1) induced acceleration of mature B-cell lymphoma 17 , which is seemingly at odds with our findings in pre-B ALL. Moreover, genetic lesions in PAX5, IKZF1, EBF1 and TCF3 are common in pre-B ALL but very rare in mature B-cell lymphomas (Extended Data Fig. 5 ).We therefore investigated whether LKB1-AMPK pathway function defines a stage-specific metabolic checkpoint during early B-cell development, when B-lymphoid transcription factors are most active. To this end, we crossed Lkb1 fl/fl mice with Cre deleter strains for deletion of Lkb1 at early (Mb1) and late (Cd21) stages of B-cell development. Although loss of Lkb1 at the pre-B cell stage resulted in a complete block of B-cell development, deletion of Lkb1 in mature Cd21 + B-cells had no substantial effect on survival and proliferation (Extended Data Fig. 4a ). These findings explain the apparent differences between pre-B ALL and mature B-cell lymphoma 17 , and also reveal a metabolic checkpoint function for Lkb1 at the pre-B-cell stage.
In both myeloid and B-lineage leukaemia cells, acute deletion of Lkb1 resulted in the loss of Ampk activity and inhibited phosphorylation of Ampk substrates (Extended Data Figs 6, 7). Although biochemical changes in response to Lkb1 deletion were similar, the functional outcomes were markedly different in myeloid and B-lymphoid cells. Letter reSeArCH survival of transplant-recipient mice in vivo (Extended Data Fig. 4 ). High expression levels of LKB1 and AMPK are associated with poor clinical outcome in patients with B-lymphoid but not myeloid leukaemia (Extended Data Fig. 5 ).
Unlike mature B-cells or myeloid cells, patient-derived pre-B ALL cells were highly sensitive to BML275, a small-molecule inhibitor of AMPK 18 . BML275 abolished AMPK enzymatic activity and AKT signalling, and induced cell death resulting from energy stress and AMP accumulation. BML275 treatment of patient-derived pre-B ALL cells obliterated glycolytic flux and mitochondrial respiration, but had no considerable effects on myeloid leukaemia or mature B-cell lymphoma cells (Extended Data Fig. 8 ). Given that both AMPK inhibition and glucocorticoid treatment reduced glucose uptake in pre-B ALL, we tested the pharmacological interactions of an AMPK inhibitor and glucocorticoids. BML275 and prednisolone demonstrated strong synergistic activity in patient-derived pre-B ALL cells, suggesting that inhibition of AMPK represents a previously unrecognized vulnerability in pre-B ALL that can be exploited in combination therapies with glucocorticoids ( Fig. 2g , Extended Data Fig. 10a and Supplementary Table 1 ).
To measure the mechanistic contribution of PAX5 target genes to PAX5-mediated tumour suppression, we performed a CRISPR-based genetic screen. For this screen, we utilized two approaches. First, we used transcriptional activation (CRISPR-a) 19 to counteract repression by PAX5, which resulted in a survival advantage when some PAX5target genes were activated, although the effects were relatively small. Second, we performed CRISPR/Cas9-mediated deletion of the PAX5 targets NR3C1 8 , TXNIP 9 and CNR2 10 , which, by comparison, provided a strong survival advantage (Extended Data Fig. 9 ). Cre-mediated loss of function of Nr3c1, Txnip and Cnr2 (Extended Data Fig. 9d ) significantly improved glucose uptake and increased ATP levels ( Fig. 3a) . Although inducible Pax5 expression caused cell death in mouse pre-B ALL cells, the tumour-suppressive effect of Pax5 was mitigated upon genetic loss of Nr3c1, Txnip and Cnr2 (Fig. 3b ). CRISPR/Cas9-mediated deletion of NR3C1, TXNIP and CNR2 in patient-derived pre-B ALL cells further corroborated the role of these negative regulators of glucose transport in human disease and PAX5-mediated tumour suppression ( Fig. 3c ).
For the past five decades, glucocorticoids have been a central component of the therapy regimen for patients with pre-B ALL. Glucocorticoids are highly active in B-lymphoid ALL, but ineffective in the treatment of myeloid leukaemia 20 ; however, the underlying reason for this difference had remained elusive. Studying patientderived leukaemia samples, we found 6-20-fold higher levels of NR3C1 protein in B-lymphoid compared to myeloid leukaemia cells ( Fig. 2b) . Whereas IKZF1 and PAX5 positively regulated NR3C1 levels, DN-IKZF1, DN-PAX5 and B-to-myeloid cell reprogramming erased NR3C1 expression ( Fig. 1 and Extended Data Fig. 3 ). We therefore tested whether B-lymphoid transcription factors set the threshold for glucocorticoid responses. Reconstitution of PAX5 and IKZF1 in pre-B ALL patient samples significantly shifted dose-response curves. Similarly, any response to dexamethasone was largely abolished upon induction of DN-IKZF1 and DN-PAX5 (Extended Data Fig. 9e ). Loss of Cnr2 and Txnip rescued prednisolone-induced cell death in pre-B ALL cells (Extended Data Fig. 9c ), suggesting that glucocorticoid responses are influenced by factors that affect glucose uptake. On this basis, we tested the drug interactions between glucocorticoids and the CNR2 agonist HU308 or the TXNIP agonists 3-O-methylglucose (3-OMG) and d-allose 21, 22 . In patient-derived pre-B ALL cells, HU308, 3-OMG or d-allose worked in synergy with glucocorticoid treatment (Extended Data Fig. 10 and Supplementary Table 1 ), suggesting that CNR2 and TXNIP cooperate with NR3C1 to exacerbate B-cell-intrinsic ATP depletion.
Our results indicate that B-lymphoid transcription factors, including PAX5 and IKZF1, exert their tumour-suppressor function, at least in part, through the transcriptional repression of glucose transport and the restriction of metabolites that can fuel the tricarboxylic acid cycle. The restriction of the supply of glucose and energy that is imposed by B-lymphoid transcription factors is necessary to prevent the malignant transformation of pre-B cells. On the basis of this scenario, we predict that transport-independent glucose metabolites can bypass the gatekeeper function of PAX5 and IKZF1. Reconstitution of PAX5 and IKZF1 was induced in haploinsufficient patient-derived pre-B ALL cells cultured in the presence of vehicle, transport-independent lipophilic methyl pyruvate or the tricarboxylic-acid-cycle intermediates dimethyl succinate (DMS) and oxaloacetate (OAA; Fig. 4a ).
Reconstitution of PAX5 and IKZF1 induced a survival disadvantage in competitive-growth assays in the presence of vehicle controls. However, dual (DMS and OAA) and triple (DMS, OAA and methyl pyruvate) combinations almost entirely prevented PAX5-and IKZF1-induced leukaemia cell death (Fig. 4a ).
Conditional expression of GFP-tagged BCR-ABL1 from a recently developed conditional knock-in allele 23 was insufficient to drive the malignant transformation of pre-B cells. BCR-ABL1 + pre-B cells from these mice remained in a pre-leukaemic state and did not give rise to overt disease. When cultured under control conditions, BCR-ABL1 + pre-B cells formed few colonies and exhibited low BCR-ABL1 kinase activity (Fig. 4b, c ). However, when BCR-ABL1 + pre-B cells were incubated for 4 weeks with DMS and OAA, colony numbers increased (vehicle-treated, 1 ± 0.5; DMS/OAA-treated, 502 ± 79), as did BCR-ABL1 expression and activity (Fig. 4b, c) . Notably, vehicle-treated BCR-ABL1 + pre-B cells failed to initiate leukaemia when injected into sub-lethally irradiated NSG (Non-obese diabetic/severe combined immunodeficient Il2rg-knockout) mouse recipients. However, six of the seven NSG recipients developed fatal disease within 5 weeks of injection when BCR-ABL1 + pre-B cells were cultured in the continuous presence of DMS and OAA (Fig. 4d, e ). In the absence of DMS and OAA, only 0.014% of BCR-ABL1 + pre-B cells expressed the BCR-ABL1-GFP fusion protein at detectable levels. Even when treated with DMS and OAA, the fraction of cells expressing BCR-ABL1-GFP did not exceed 1% (Fig. 4b ), suggesting that metabolite-induced transformation is a rare event.
During early B-cell development, pre-B cells are under intense selective pressure. Collateral damage during V(D)J-recombination represents a main driver of malignant transformation 24, 25 . We propose that B-lymphoid transcription factors function as metabolic gatekeepers, limiting the supply of glucose and energy to levels that are below the minimum requirements for malignant transformation (Fig. 4f ). Preleukaemic B-cell clones carrying oncogenic lesions are frequently found in neonatal cord blood 26, 27 . In addition, small fractions of normal B cells in healthy adults carry silent oncogenes 28, 29 . These findings indicate that pre-leukaemic B-cell clones frequently occur in healthy individuals, both during childhood and later in life. We conclude that B-lymphoid repression of glucose uptake and energy supply represents a previously unrecognized metabolic barrier against malignant pre-Bcell transformation and that TXNIP, CNR2 and AMPK are novel targets for the treatment of pre-B ALL.
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Primary human samples and cell lines. Pre-B acute lymphoblastic leukaemia (ALL) cells were obtained from patients who gave informed consent in compliance with the guidelines of the Internal Review Board of the University of California San Francisco (Supplementary Table 2 ). Leukaemia cells from bone marrow biopsy of patients with ALL were xenografted into sublethally irradiated NOD/SCID (nonobese diabetic/severe combined immunodeficient) mice via tail vein injection. After passaging, leukaemia cells were collected. Cells were cultured on OP9 stroma cells in minimum essential medium-α (MEMα ; Invitrogen), supplemented with 20% fetal bovine serum (FBS), 2 mM l-glutamine, 1 mM sodium pyruvate, 100 IU/ml penicillin and 100 μ g/ml streptomycin. Primary chronic myeloid leukaemia (CML) cases were obtained with informed consent from the University Hospital Jena in compliance with institutional internal review boards (including the IRB of the University of California San Francisco; Supplementary Table 3 ). Cells were cultured in Iscove's modified Dulbecco's medium (IMDM; Invitrogen) supplemented with 20% BIT serum substitute (StemCell Technologies); 100 IU/ml penicillin and 100 μ g/ml streptomycin; 25 μ mol/l β -mercaptoethanol; 100 ng/ml SCF; 100 ng/ml G-CSF; 20 ng/ml FLT3; 20 ng/ml IL-3; and 20 ng/ml IL-6. Human cell lines (Supplementary Table 2 ) were obtained from DSMZ and were cultured in Roswell Park Memorial Institute medium (RPMI-1640; Invitrogen) supplemented with GlutaMAX containing 20% FBS, 100 IU/ml penicillin and 100 μ g/ml streptomycin. Cell cultures were kept at 37 °C in a humidified incubator in a 5% CO 2 atmosphere. None of the cell lines used was found in the database of commonly misidentified cell lines maintained by ICLAC and NCBI Biosample. All cell lines were authenticated by STR profiles and tested negative for mycoplasma. Small-molecule inhibitors and activators and metabolites. BML275 (watersoluble) and imatinib were obtained from Santa Cruz Biotechnology and LC Laboratories, respectively. Stock solutions were prepared in DMSO or sterile water at 10 mmol/l and stored at − 20 °C. Prednisolone and dexamethasone (watersoluble) were purchased from Sigma-Aldrich and were resuspended in ethanol or sterile water, respectively, at 10 mmol/l. Stock solutions were stored at − 20 °C. Fresh solutions (pH-adjusted) of methyl pyruvate, OAA, 3-OMG (an agonist of TXNIP), d-allose (an agonist of TXNIP) and recombinant insulin (Sigma-Aldrich) were prepared for each experiment. DMS was obtained from Acros Organics, and fresh solutions (pH-adjusted) were prepared before each experiment. For competitive-growth assays, 5 mmol/l methyl pyruvate, 5 mmol/l dimethyl succinate (DMS) and 5 mmol/l OAA were used. The CNR2 agonist HU308 was obtained from Cayman Chemical. Table 4 ) younger than 6 weeks of age without signs of inflammation. All mouse experiments were conducted in compliance with institutional approval by the University of California, San Francisco Institutional Animal Care and Use Committee. Bone marrow cells were obtained by flushing cavities of femur and tibia with PBS. After filtration through a 70-μ m filter and depletion of erythrocytes using a lysis buffer (BD PharmLyse, BD Biosciences), washed cells were either frozen for storage or subjected to further experiments.
Mouse leukaemia models. To avoid inflammation-related effects in mice, bone marrow cells were extracted from mice (Supplementary
Bone marrow cells were cultured in IMDM (Invitrogen) with GlutaMAX containing 20% fetal bovine serum, 100 IU/ml penicillin, 100 μ g/ml streptomycin and 50 μ M β -mercaptoethanol. To generate pre-B ALL (Ph + ALL-like) cells, bone marrow cells were cultured in 10 ng/ml recombinant mouse IL-7 (PeproTech) and retrovirally transformed by BCR-ABL1. BCR-ABL1-transformed pre-B ALL cells were propagated only for short periods of time and usually not for longer than 2 months to avoid acquisition of additional genetic lesions during long-term cell culture. To generate myeloid leukaemia (CML-like) cells, the myeloid-restricted protocol described previously 30 was used. Bone marrow cells were cultured in 10 ng/ml recombinant mouse IL-3, 25 ng/ml recombinant mouse IL-6, and 50 ng/ml recombinant mouse SCF (PeproTech) and retrovirally transformed by BCR-ABL1. Immunophenotypic characterization was performed by flow cytometry. For conditional deletion, a 4-OHT-inducible, Cre-mediated deletion system was used. For retroviral constructs used, see Supplementary Table 5 . Table 5 ) was performed using Lipofectamine 2000 (Invitrogen) with Opti-MEM medium (Invitrogen). Retroviral supernatant was produced by co-transfecting HEK 293FT cells with the plasmids pHIT60 (gag-pol) and pHIT123 (ecotropic env). Lentiviral supernatant was produced by co-transfecting HEK 293FT cells with the plasmids pCDNL-BH and VSV-G or EM140. 293FT cells were cultured in high glucose Dulbecco's modified Eagle's medium (DMEM, Invitrogen) with GlutaMAX containing 10% fetal bovine serum, 100 IU/ml penicillin, 100 μ g/ml streptomycin, 25 mmol/l HEPES, 1 mmol/l sodium pyruvate and 0.1 mmol/l non-essential amino acids. Regular medium was replaced after 16 h by growth medium containing 10 mmol /l sodium butyrate. After incubation for 8 h, the medium was changed back to regular growth medium. After 24 h, retroviral supernatant was collected, filtered through a 0.45-μ m filter and loaded by centrifugation (2,000g, 90 min at 32 °C) onto 50 μ g/ml RetroNectin-(Takara) coated non-tissue 6-well plates. Lentiviral supernatant produced with VSV-G was concentrated using Lenti-X Concentrator (Clontech), loaded onto RetroNectin-coated plates and incubated for 15 min at room temperature. Lentiviral supernatant produced with EM140 was collected, loaded onto RetroNectin-coated plates and incubated for 30 min at room temperature. Per well, 2-3 × 10 6 cells were transduced by centrifugation at 600g for 30 min and maintained for 48 h at 37 °C with 5% CO 2 before transferring into culture flasks. For cells transduced with lentiviral supernatant produced with EM140, supernatant was removed the day after transduction and replaced with fresh culture medium. Cells transduced with oestrogen-receptor fusion proteins were induced with 4-OHT (1 μ mol/l). Cells transduced with constructs carrying an antibiotic-resistance marker were selected with its respective antibiotic. Inducible gain-and loss-of-function of IKZF1 and PAX5. For loss-of-function studies, dominant-negative variants of IKZF1 (DN-IKZF1, lacking the IKZF1 zinc fingers 1-4) and PAX5 (DN-PAX5; PAX5-ETV6 fusion) were cloned from patient samples. Expression of DN-IKZF1 was induced by doxycycline (1 μ g/ml), while activation of DN-PAX5 was induced by 4-OHT (1 μ g/ml) in patientderived pre-B ALL cells carrying IKZF1 and PAX5 wild-type alleles, respectively. Inducible reconstitution of wild-type IKZF1 and PAX5 in haploinsufficient pre-B ALL cells carrying deletions of either IKZF1 (IKZF1 Δ ) or PAX5 (PAX5 Δ ) were also studied. Lentiviral constructs used are listed in Supplementary Table 5 . A doxycycline-inducible Tet On vector system was used for inducible expression of PAX5 in mouse BCR-ABL1 pre-B ALL. The retroviral constructs used are listed in Supplementary Table 5 .
Retroviral and lentiviral constructs and transduction. Transfection of retroviral constructs (Supplementary
CEBPα-mediated reprogramming of pre-B cells into the myeloid lineage.
To study the effects of B-cell-versus myeloid-lineage identity in genetically identical mouse leukaemia cells, a doxycycline-inducible Tet On -CEBPα vector system 31 was used to reprogram B cells. Mouse BCR-ABL1 pre-B ALL cells expressing doxycycline-inducible CEBPα or an empty vector were induced with doxycycline (1 μ g/ml). Conversion from the B-cell lineage (CD19 + Mac1 − ) to the myeloid lineage (CD19 − Mac1 + ) was monitored by flow cytometry. For western blots, B-lineage cells (CD19 + Mac1 − ) and CEBPα -reprogrammed cells (CD19 − Mac1 + ) were sorted from cells expressing an empty vector or CEBPα , respectively, following doxycycline induction. For metabolic assays, sorted B-lineage cells and CEBP α -reprogrammed cells were cultured (with doxycycline) for 2 days following sorting, and were then seeded in fresh medium for measurement of glucose consumption (normalized to cell numbers) and total ATP levels (normalized to total protein).
To study Lkb1 deletion in the context of CEBPα -mediated reprogramming, BCR-ABL1-transformed Lkb1 fl/fl pre-B ALL cells expressing doxycyclineinducible CEBPα were transduced with 4-OHT(1 μ g/ml) inducible Cre-GFP (Cre-ER T2 -GFP). Without sorting for GFP + cells, cells were induced with doxycycline and 4-OHT. Viability (expressed as relative change of GFP + cells) was measured separately in B-lineage (gated on CD19 + Mac1 − ) and myeloid lineage (gated on CD19 − Mac1 + ) populations.
To study whether Lkb1 deletion causes CEBPα -dependent effects on metabolism and signalling, Lkb1 fl/fl BCR-ABL1 B-lineage ALL cells expressing doxycyclineinducible CEBPα or an empty vector were transduced with 4-OHT-inducible Cre-GFP. After sorting for GFP + populations, cells were induced with doxycycline. B-lineage cells (CD19 + Mac1 − ) and CEBPα -reprogrammed cells (CD19 − Mac1 + ) were sorted from cells expressing an empty vector or CEBPα , respectively. Sorted cells were cultured with doxycycline and induced with 4-OHT. Protein lysates were collected on day 2 following 4-OHT induction. For metabolomics, sorted cells were re-seeded in fresh medium on day 2 following 4-OHT induction and collected for metabolite extraction. CRISPR-mediated gene editing. For CRISPR/Cas9-mediated deletion of target genes, all constructs including lentiviral vectors expressing gRNA and Cas9 nuclease were purchased from Transomic Technologies ( Supplementary Table 5 ; see Supplementary Table 6 for gRNA sequences). In brief, patient-derived pre-B ALL cells transduced with GFP-tagged, 4-OHT-inducible PAX5 or an empty vector were transduced with pCLIP-hCMV-Cas9-Nuclease-Blast. Blasticidin-resistant cells were subsequently transduced with pCLIP-hCMV-gRNA-RFP. Non-targeting gRNA was used as control.
Constructs including lentiviral vectors expressing gRNA and dCas9-VPR used for CRISPR/dCas9-mediated activation of gene expression are listed in Supplementary Table 5 . Nuclease-null Cas9 (dCas9) fused with VP64-p65-Rta (VPR) was cloned from SP-dCas9-VPR (a gift from G. Church; Addgene plasmid #63798) and then subcloned into pCL6 vector with a blasticidin-resistant marker. gRNA sequences ( Supplementary Table 6 ) targeting the transcriptional start site Letter reSeArCH of each specific gene were obtained from public databases (http://sam.genomeengineering.org/ and http://www.genscript.com/gRNA-database.html) 32 . gBlocks Gene Fragments were used to generate single-guide RNAs (sgRNAs) and were purchased from Integrated DNA Technologies, Inc. Each gRNA was subcloned into pCL6 vector with a dsRed reporter. Patient-derived pre-B ALL cells transduced with either GFP-tagged inducible PAX5 or an empty vector were transduced with pCL6-hCMV-dCas9-VPR-Blast. Blasticidin-resistant cells were used for subsequent transduction with pCL6-hCMV-gRNA-dsRed, and dsRed + cells were further analysed by flow cytometry. For each target gene, 2-3 sgRNA clones were pooled together to generate lentiviruses. Non-targeting gRNA was used as control. To elucidate the mechanistic contribution of PAX5 targets, the percentage of GFP + cells carrying gRNA(s) for each target gene was monitored by flow cytometry upon inducible activation of GFP-tagged PAX5 or an empty vector in patient-derived pre-B ALL cells in competitive-growth assays. Western blotting. Cells were lysed in CelLytic buffer (Sigma-Aldrich) supplemented with a 1% protease inhibitor cocktail (Thermo Fisher Scientific). A total of 20 μ g of protein mixture per sample was separated on NuPAGE (Invitrogen) 4-12% Bis-Tris gradient gels or 4-20% Mini-PROTEAN TGX precast gels, and transferred onto nitrocellulose membranes (Bio-Rad). The primary antibodies used are listed in Supplementary Table 7 . For protein detection, the WesternBreeze Immunodetection System (Invitrogen) was used, and light emission was detected by either film exposure or the BioSpectrum Imaging system (UPV). Flow cytometry. Approximately 10 6 cells per sample were resuspended in PBS blocked using Fc blocker for 10 min on ice, followed by staining with the appropriate dilution of the antibodies or their respective isotype controls for 15 min on ice. Cells were washed and resuspended in PBS with propidium iodide (0.2 μ g/ml) or DAPI (0.75 μ g/ml) as a dead-cell marker. The antibodies used for flow cytometry are listed in Supplementary Table 7 . For competitive-growth assays, the percentage of GFP + cells was monitored by flow cytometry. For annexin V staining, annexin V binding buffer (BD Bioscience) was used instead of PBS and 7-aminoactinomycin D (7AAD; BD Bioscience) instead of propidium iodide. Phycoerythrin-labelled annexin V was purchased from BD Bioscience. For BrdU staining, the BrdU Flow Kit was purchased from BD Bioscience and used according to the manufacturer's protocol. Colony-forming assay. Methylcellulose colony-forming assays were performed with 10,000 BCR-ABL1 pre-B ALL cells. Cells were resuspended in mouse MethoCult medium (StemCell Technologies) and cultured on 3-cm dishes, with an extra water supply dish to prevent evaporation. Images were taken and colony numbers were counted after 14 days. Cell viability assay and determination of viable cell counts. Cell viability upon the genetic loss of function of target genes and/or inducible expression of PAX5 was monitored by flow cytometry using propidium iodide (0.2 μ g/ml) as a deadcell marker. To study the effects of an AMPK inhibitor (BML275), glucocorticoids (dexamethasone and prednisolone), CNR2 agonist (HU308), or TXNIP agonists (3-OMG and d-allose), 40,000 human or mouse leukaemia cells were seeded in a volume of 80 μ l in complete growth medium on opaque-walled, white 96-well plates (BD Biosciences). Compounds were added at the indicated concentrations giving a total volume of 100 μ l per well. After culturing for 3 days, cells were subjected to CellTiter-Glo Luminescent Cell Viability Assay (Promega). Relative viability was calculated using baseline values of cells treated with vehicle control as a reference. Combination index (CI) was calculated using the CalcuSyn software to determine interaction (synergistic, CI < 1; additive, CI = 1; or antagonistic, CI > 1) between the two agents. Constant ratio combination design was used. Concentrations of BML275, d-allose, 3-OMG and HU308 used are indicated in the figures. Concentrations of Dex used were tenfold lower than those of BML275. Concentrations of prednisolone used were twofold lower than those of BML275.
To determine the number of viable cells, the trypan blue exclusion method was applied, using the Vi-CELL Cell Counter (Beckman Coulter). Single-locus quantitative ChIP and ChIP-seq data. ChIP was performed as described previously 33 . Chromatin from fixed patient-derived Ph + ALL cells (ICN1) was isolated and sonicated to 100-500-bp DNA fragments. Chromatin fragments were immunoprecipitated with either IgG (as a control) or anti-Pax5 antibody (see Supplementary Table 7 ). Following reversal of crosslinking by formaldehyde, specific DNA sequences were analysed by quantitative real-time PCR (see Supplementary Table 8 for primers). Primers were designed according to ChIP-seq tracks for PAX5 antibodies in B lymphocytes (ENCODE, Encyclopedia of DNA Elements, GM12878). ChIP-seq tracks for PAX5, IKZF1, EBF1 and TCF3 antibodies in a normal B-cell sample (ENCODE GM12878, UCSC genome browser) on INSR, GLUT1, GLUT3, GLUT6, HK2, G6PD, NR3C1, TXNIP, CNR2 and LKB1 gene promoter regions are shown. CD19 and ACTA1 served as a positive and a negative control gene, respectively. The y axis represents the normalized number of reads per million reads for peak summit for each track. The ChIP-seq peaks were called by the MACS peak-caller by comparing read density in the ChIP experiment relative to the input chromatin control reads, and are shown as bars under each wiggle track. Gene models are shown in UCSC genome browser hg19. Glucose and ATP measurements. Extracellular glucose levels were measured using the Amplex Red Glucose/Glucose Oxidase Assay Kit (Invitrogen), according to the manufacturer's protocol. Glucose concentrations were measured in fresh and spent medium. Total ATP levels were measured using the ATP Bioluminescence Assay Kit CLS II (Roche) according to the manufacturer's protocol. In fresh medium, 1 × 10 6 cells per ml were seeded and treated as indicated in the figure legends. Relative levels of glucose consumed and total ATP are shown. All values were normalized to cell numbers (Figs 1b, c, 2c (glucose uptake), 3a and Extended Data Figs 2c, 4f, 6d) or total protein (Fig. 2c, ATP levels) . Numbers of viable cells were determined by applying trypan blue dye exclusion, using the Vi-CELL Cell Counter (Beckman Coulter). Metabolic assays using the XFe24 Flux Analyzer. Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were measured using a Seahorse XFe24 Flux Analyzer with an XF Cell Mito Stress Test Kit and XF Glycolysis Stress Test Kit (Seahorse Bioscience) according to the manufacturer's instructions. All compounds and materials were obtained from Seahorse Bioscience. In brief, 1.5 × 10 5 cells per well were plated using Cell-Tak (BD Biosciences). Following incubation in XF-Base medium supplemented with glucose and GlutaMAX for 1 h at 37 °C (non-CO 2 incubator) for pH stabilization, OCR was measured at the resting stage (basal respiration in XF Base medium supplemented with GlutaMax and glucose) and in response to oligomycin (1 μ mol/l; mitochondrial ATP production), mitochondrial uncoupler FCCP (5 μ mol/l; maximal respiration), and respiratory chain inhibitor antimycin and rotenone (1 μ mol/l). Spare respiratory capacity is the difference between maximal respiration and basal respiration. ECAR was measured under specific conditions to generate glycolytic profiles. Following incubation in glucose-free XF Base medium supplemented with GlutaMAX for 1 h at 37 °C (non-CO 2 incubator) for pH stabilization, basal ECAR was measured. Following measurement of the glucose-deprived, basal ECAR, changes in ECAR upon the sequential addition of glucose (10 mmol/l; glycolysis), oligomycin (1 μ mol/l; glycolytic capacity), and 2-deoxyglucose (0.1 mol/l) were measured. Glycolytic reserve was determined as the difference between oligomycin-stimulated glycolytic capacity and glucose-stimulated glycolysis. All values were normalized to cell numbers (Extended Data Fig. 2c ) or total protein (Extended Data Figs 3a, 7a, b, 8f ) and are shown as the fold change relative to basal ECAR or OCR. Metabolite extraction and mass-spectrometry-based analysis. Metabolite extraction and mass-spectrometry-based analysis were performed as described previously 34 . Metabolites were extracted from 2 × 10 5 cells per sample using the methanol/water/chloroform method. After incubation at 37 °C for the indicated time, cells were rinsed with 150 mM ammonium acetate (pH 7.3), and 400 μ l cold 100% methanol (Optima* LC/MS, Fisher) and then 400 μ l cold water (HPLC-Grade, Fisher) was added to cells. A total of 10 nmol norvaline (Sigma) was added as internal control, followed by 400 μ l cold chloroform (HPLC-Grade, Fisher). Samples were vortexed three times over 15 min and spun down at top speed for 5 min at 4 °C. The top layer (aqueous phase) was transferred to a new Eppendorf tube, and samples were dried on Vacufuge Plus (Eppendorf) at 30 °C. Extracted metabolites were stored at − 80 °C. For mass spectrometry-based analysis, the metabolites were resuspended in 70% acetonitrile and 5 μ l used for analysis with a mass spectrometer. The mass spectrometer (Q Exactive, Thermo Scientific) was coupled to an UltiMate3000 RSLCnano HPLC. The chromatography was performed with 5 mM NH 4 AcO (pH 9.9) and acetonitrile at a flow rate of 300 μ l/min starting at 85% acetonitrile, going to 5% acetonitrile at 18 min, followed by an isocratic step to 27 min and re-equilibration to 34 min. The separation was achieved on a Luna 3u NH2 100A (150 × 2 mm) (Phenomenex). The Q Exactive was run in polarity switching mode (+ 3 kV/− 2.25 kV). Metabolites were detected based on retention time (t R ) and on accurate mass (± 3 p.p.m.). Metabolite quantification was performed as area-under-the-curve (AUC) with TraceFinder 3.1 (Thermo Scientific). Data analysis was performed in R (https://www.r-project.org/), and data were normalized to the number of cells. Relative amounts were log 2 -transformed, median-centred and are shown as a heat map. Oncogenic priming of Mb1-Cre; Bcr +/LSL-BCR/ABL B-cell precursor cells. To generate a model for pre-leukaemic B cell precursors expressing BCR-ABL1, BCR-ABL1 knock-in mice were crossed with Mb1-Cre deleter strain (Mb1-Cre; Bcr +/LSL-BCR/ABL ) for excision of a stop-cassette in early pre-B cells. Bone marrow cells collected from Mb1-Cre; Bcr +/LSL-BCR/ABL mice cultured in the presence of IL-7 were primed with vehicle control or a combination of OAA (8 mmol/l), DMS (8 mmol/l) and insulin (210 pmol/l). Following a week of priming, cells were maintained and expanded in the presence of IL-7, supplemented with vehicle control or a combination of OAA (0.8 mmol/l) and DMS (0.8 mmol/l) for 4 weeks. Pre-B cells from Mb1-Cre; Bcr +/LSL-BCR/ABL mice expressed low levels of BCR-ABL1 tagged Letter reSeArCH to GFP, and were analysed by flow cytometry for surface expression of GFP and CD19. The methylcellulose colony-forming assays were performed with 10,000 cells treated with vehicle control or metabolites. Cells were resuspended in mouse MethoCult medium (StemCell Technologies) and cultured on 3-cm diameter dishes, with an extra water supply dish to prevent evaporation. Images were taken and colony numbers counted after 14 days.
For in vivo transplantation experiments, cells were treated with vehicle control or metabolites (OAA/DMS) for 6 weeks. One million cells were intravenously injected into sublethally irradiated (250 cGy) 6-8-week-old female NSG mice (n = 7 per group). Mice were randomly allocated into each group, and the minimal number of mice in each group was calculated by using the 'cpower' function in R/Hmisc package. No blinding was used. Each mouse was killed when it became terminally sick and showed signs of leukaemia burden (hunched back, weight loss and inability to move). The bone marrow and spleen were collected for flow cytometry analyses for leukaemia infiltration (CD19, B220). After 63 days, all remaining mice were killed and bone marrow and spleens from all mice were analysed by flow cytometry. Statistical analysis was performed using the Mantel-Cox log-rank test. All mouse experiments were in compliance with institutional approval by the University of California, San Francisco Institutional Animal Care and Use Committee.
In vivo experiments. Following cytokine-independent proliferation, BCR-ABL1transformed Lkb1 fl/fl or AMPKa2 fl/fl pre-B ALL cells were transduced with 4-OHTinducible Cre or an empty vector control. For ex vivo deletion, deletion was induced 24 h before injection. For in vivo deletion, deletion was induced by 4-OHT (0.4 mg per mouse; intraperitoneal injection). Approximately 10 6 cells were injected into each sublethally irradiated (250 cGy) NOD/SCID mouse. Seven mice per group were injected via the tail vein.
We randomly allocated 6-8-week-old female NOD/SCID or NSG mice into each group. The minimal number of mice in each group was calculated using the 'cpower' function in R/Hmisc package. No blinding was used. When a mouse became terminally sick and showed signs of leukaemia burden (hunched back, weight loss and inability to move), it was killed and the bone marrow and/or spleen were collected for flow cytometry analyses for leukaemia infiltration. Statistical analysis was performed by Mantel-Cox log-rank test. In vivo expansion and leukaemia burden were monitored by luciferase bioimaging. Bioimaging of leukaemia progression in mice was performed at the indicated time points using an in vivo IVIS 100 bioluminescence/optical imaging system (Xenogen). d-luciferin (Promega) dissolved in PBS was injected intraperitoneally at a dose of 2.5 mg per mouse 15 min before measuring the luminescence signal. General anaesthesia was induced with 5% isoflurane and continued during the procedure with 2% isoflurane introduced through a nose cone. All mouse experiments were in compliance with institutional approval by the University of California, San Francisco Institutional Animal Care and Use Committee. Statistical analysis and reproducibility. Data are shown as mean ± s.d. unless stated. Statistical significance was analysed by using Grahpad Prism software or R software (https://www.r-project.org/) by using two-tailed t-test, two-way ANOVA, or log-rank test as indicated in figure legends. Significance was considered at P < 0.05. For in vitro experiments, no statistical methods were used to predetermine the sample size. For in vivo transplantation experiments, the minimal number of mice in each group was calculated through use of the 'cpower' function in the R/Hmisc package. No animals were excluded. Overall survival and relapse-free survival data were obtained from GEO accession number GSE11877 (refs 35, 36) and TCGA. Kaplan-Meier survival analysis was used to estimate overall survival and relapse-free survival. Patients with high risk pre-B ALL (COG clinical trial, P9906, n = 207; Supplementary Table 10 ) were segregated into two groups on the basis of high or low mRNA levels with respect to the median mRNA values of the probe sets for the gene of interest. A log-rank test was used to compare survival differences between patient groups. R package 'survival' Version 2.35-8 was used for the survival analysis and Cox proportional hazards regression model in R package for the multivariate analysis (https://www.r-project.org/). The investigators were not blinded to allocation during experiments and outcome assessment. Experiments were repeated to ensure reproducibility of the observations. Data availability. Gel scans are provided in Supplementary Fig. 1 . Gene expression data were obtained from the GEO database accession numbers GSE32330 (ref. 12 ), GSE52870 (ref. 37) , and GSE38463 (ref. 38) . Patient-outcome data were derived from the National Cancer Institute TARGET Data Matrix of the Children's Oncology Group (COG) Clinical Trial P9906 (GSE11877) 35, 36 and from TCGA (the Cancer Genome Atlas). GEO accession details are provided in Supplementary  Tables 9 and 10 . ChIP-seq tracks for PAX5, IKZF1, EBF1 and TCF3 antibodies in a normal B-cell sample (ENCODE GM12878, UCSC genome browser) on INSR, GLUT1, GLUT3, GLUT6, HK2, G6PD, NR3C1, TXNIP, CNR2 and LKB1 gene promoter regions are shown in UCSC genome browser hg19. All other data are available from the corresponding author upon reasonable request. and capacity (ECAR), glucose uptake, and ATP levels (normalized to cell numbers) were studied in Pax5 wild-type and Pax5 haploinsufficient pre-B cells in the presence or absence of a BCR-ABL1-transgene. Data shown as mean ± s.d. from three independent experiments and assessed by twotailed t-test (b, left; c) or two-way ANOVA (b, right). For gel source data, see Supplementary Fig. 1. 
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